Patents
Literature
3 results about "Cystine knot" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
A cystine knot is a protein structural motif containing three disulfide bridges (formed from pairs of cysteine residues). The sections of polypeptide that occur between two of them form a loop through which a third disulfide bond passes, forming a rotaxane substructure. The cystine knot motif stabilizes protein structure and is conserved in proteins across various species. There are three types of cystine knot, which differ in the topology of the disulfide bonds...
Cystine knot domain fusion protein dimer
The present application relates to a protein dimer formed from a first fusion protein and a second fusion protein, wherein the first fusion protein comprises a cystine knot domain (CK) fused to a first pharmaceutically active protein and the second fusion protein comprises a CK domain fused to a second pharmaceutically active protein, wherein the two fusion proteins are covalently linked via their CK domains. The present application further relates to the individual fusion proteins, polynucleotides encoding the fusion proteins, vectors comprising the polynucleotides, and host cells comprising the vectors.
Owner:OCTAPHARMA AG
Rhabdovirus g protein having one or more cysteine-rich regions and uses thereof
PendingCN122422338ACystine knotViral glycoprotein
Owner:WILLIARD CORP
Polypeptide for inhibiting KRAS protein activation and application thereof
PendingCN121627903AFusion with degradation motifPeptide/protein ingredientsCystine knotKras mutation
The invention provides a polypeptide capable of inhibiting activated KRAS protein in a broad spectrum mode, the polypeptide comprises a KRAS targeting structural domain, and the KRAS targeting structural domain is an RAS binding structural domain (RBD)-cysteine-rich structural domain (CRD) of RAF1, an RBD structural domain of RAF1 or an RBD structural domain of SIN1. The invention further provides a combined administration method for broad-spectrum inhibition of multiple KRAS mutation tumors. The method disclosed by the invention can be used for treating various KRAS mutant tumors, and compared with a single micromolecular anticancer drug, the tumor inhibition effect can be remarkably improved.
Owner:SINOVAC RES & DEV CO LTD